Cannabidiol-type cannabinoid compound
The present invention relates to a cannabidiol (CBD) type cannabinoid compound for use as a medicament. The CBD-type cannabinoid, 6-hydroxy cannabidivarin (6-OH CBDV), is a metabolite of cannabidivarin (CBDV). The cannabinoid can be produced by synthetic means and a method for the production of 6-OH CBDV is described herein. In addition, disclosed herein are data which demonstrate the efficacy of 6-OH CBDV in a model of disease.
1. A method of treating epilepsy in a subject in need thereof, comprising administering a therapeutically effective dose of 6-hydroxy cannabidivarin (6-OH CBDV) to the subject.
2. The method of claim 1 , wherein the 6-OH CBDV is in the form of a synthetic compound.
3. The method of claim 1 , wherein the 6-OH CBDV is in the form of a pure or isolated compound.
4. The method of claim 1 , wherein the dose of 6-OH CBDV is greater than 100 mg/kg/day.
5. The method of claim 1 , wherein the dose of 6-OH CBDV is less than 100 mg/kg/day.
6. The method of claim 1 , wherein the subject is a mammal.
7. The method of claim 6 , wherein the mammal is a human.
8. The method of claim 6 , wherein the mammal is a dog.
9. The method of claim 1 , wherein the dose of 6-OH CBDV is less than 10 mg/kg/day.
10. The method of claim 1 , wherein the dose of 6-OH CBDV ranges from 10 mg/kg/day to 100 mg/kg/day.
11. The method of claim 1 , wherein the dose of 6-OH CBDV ranges from 20 mg/kg/day to 100 mg/kg/day.
12. The method of claim 1 , wherein the dose of 6-OH CBDV ranges from 50 mg/kg/day to 100 mg/kg/day.
13. The method of claim 1 , wherein the dose of 6-OH CBDV ranges from greater than 100 mg/kg/day to 1500 mg/kg/day.
14. The method of claim 1 , wherein the dose of 6-OH CBDV ranges from greater than 100 mg/kg/day to 1000 mg/kg/day.
15. The method of claim 1 , wherein the dose of 6-OH CBDV ranges from greater than 100 mg/kg/day to 750 mg/kg/day.
16. The method of claim 1 , wherein the dose of 6-OH CBDV ranges from greater than 100 mg/kg/day to 500 mg/kg/day.
17. The method of claim 1 , wherein the treatment comprises producing an anticonvulsive effect in the subject.
18. The method of claim 1 , wherein the treatment reduces seizures in the subject or increases a threshold of seizures in the subject, compared to a control.
19. The method of claim 1 , wherein the treatment comprises treating tonic seizures and/or tonic-clonic seizures.
20. The method of claim 1 , wherein the 6-OH CBDV is at least 96.7% pure as measured by HPLC.